Analysed SANOFI-ADR (SNY:NASDAQ) News Sources
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough
21-08-2026
barchart.com
Atrial Fibrillation Market Trends and Forecast 2026-2035 Featuring Profiles of Abbott, Boston Scientific, Medtronic, Johnson & Johnson, Novartis, and Sanofi
26-08-2026
yahoo.com
Cytotoxic Drugs Market Report Now Available — Forecasts Market Growth from $16.21B (2026) to $21.06B by 2031, Profiling Pfizer, Roche, Novartis, AstraZeneca, Sanofi, and 15 Other Key Players
28-08-2026
yahoo.com
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
28-08-2026
yahoo.com
AimwellBio Secures Proprietary Behavioral AI Portfolio Backed by Oxford Science and Sanofi Pilot; Inventor Dr. Chris A. Jones Joins Board of Advisors
17-08-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
18-08-2026
yahoo.com
Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
26-08-2026
fool.com
What is the current price of SANOFI-ADR (SNY:NASDAQ)?
The current price of SANOFI-ADR (SNY:NASDAQ) is $44.77.
SANOFI-ADR (SNY:NASDAQ) absolute price change since previous trading day?
The absolute price change of SANOFI-ADR (SNY:NASDAQ) since the previous trading day is $-0.07.
SANOFI-ADR (SNY:NASDAQ) percentage price change since previous trading day?
The percentage price change of SANOFI-ADR (SNY:NASDAQ) since the previous trading day is -0.1561%.
What is the most recent average sentiment score for SANOFI-ADR (SNY:NASDAQ)?
The most recent average sentiment score for SANOFI-ADR (SNY:NASDAQ) is 49 out of 100.
What is the most recent average sentiment for SANOFI-ADR (SNY:NASDAQ)?
The most recent sentiment for SANOFI-ADR (SNY:NASDAQ) is .
SEC-8K** Filing Available For SANOFI-ADR (SNY:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.